Philip Wood - Swedish Orphan Head Haematology

All Insiders . Germany . 
Stock . Swedish Orphan Biovitrum . Stakeholders . Insider . Philip Wood
B6E Stock  EUR 26.48  0.04  0.15%   

Insider

Philip Wood is Head Haematology of Swedish Orphan Biovitrum
Age 55
Phone46 86 97 20 00
Webhttps://www.sobi.com

Swedish Orphan Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.
Swedish Orphan Biovitrum has accumulated 8.78 B in total debt with debt to equity ratio (D/E) of 39.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Christophe WeberTakeda Pharmaceutical
57
Nadeem SarwarEisai Co
N/A
John KellerShionogi Co
58
Gabriele RicciTakeda Pharmaceutical
45
Andrew PlumpTakeda Pharmaceutical
58
Ryuichi KiyamaShionogi Co
N/A
Kevin MannixTeva Pharmaceutical Industries
N/A
Eli ShaniTeva Pharmaceutical Industries
N/A
Constantine SaroukosTakeda Pharmaceutical
52
Salvatore AlesciTakeda Pharmaceutical
N/A
Dominique BeryIpsen SA
52
Francois GarnierIpsen SA
61
Sven DethlefsTeva Pharmaceutical Industries
54
Karen SantiagoCatalent
52
Erez MBADr Reddys Laboratories
55
Gary HendlerEisai Co
57
David LoewIpsen SA
56
Eric DrapeTeva Pharmaceutical Industries
61
Gunupati BEDr Reddys Laboratories
63
Mark SabagTeva Pharmaceutical Industries
52
Haruhiko HirateTakeda Pharmaceutical
66
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany. Swedish Orphan Biovitrum (B6E) is traded on Frankfurt Exchange in Germany and employs 1,556 people.

Management Performance

Return On Equity0.11
Return On Asset0.0555

Swedish Orphan Biovitrum Leadership Team

Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
Konstantina Karampela, Director Operations
Christine Wesstrom, Head Operations
Guido Oelkers, CEO Pres
Thomas Larsen, Head Relations
Pablo Mora, Head Access
Armin MD, Head Affairs
Philip Wood, Head Haematology
Anders MD, Head Officer
Torbjrn Hallberg, G HR
Daniel Rankin, Head Devel
Henrik Stenqvist, Chief Officer

Swedish Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.11
Return On Asset0.0555
Profit Margin0.14 %
Current Valuation6.67 B
Shares Outstanding295.99 M
Shares Owned By Insiders4.00 %
Shares Owned By Institutions69.59 %
Price To Earning18.28 X
Price To Book2.47 X
Price To Sales3.66 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Swedish Stock

Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY